George K Avetian1, Phillip Fiuty2, Silvana Mazzella3, Dave Koppa2, Vivian Heye2, Pratibha Hebbar4. 1. a Delaware County , Media , PA , USA. 2. b Santa Fe Mountain Center Harm Reduction Program , Santa Fe , NM , USA. 3. c Prevention Point Philadelphia , Philadelphia , PA , USA. 4. d Synchrony Medical Communications LLC , West Chester , PA , USA.
Abstract
OBJECTIVE: Naloxone hydrochloride, an opioid antagonist, has been approved as a concentrated 4 mg dose intranasal formulation for the emergency treatment of known or suspected opioid overdose. This new formulation is easier to use and contains a higher dose of naloxone compared with earlier, unapproved kits. A survey of first responders and community-based organizations was conducted to understand initial real-world experiences with this new formulation for opioid overdose reversal. METHODS: In August 2016, 152 US organizations known to have received units of the approved 4 mg dose/unit naloxone nasal spray (Narcan®1 nasal spray 4 mg; NNS) were surveyed regarding experiences using this formulation and availability of recorded data on these cases. Descriptive statistics were calculated based on the number of responses received for each item. RESULTS: Eight first-responder or community-based organizations provided case report data on 261 attempted overdose reversals using NNS, with survival reported for 245 cases. Successful overdose reversals were reported in 98.8% (242/245) of cases; most cases (73.5%; 125/170) reported a time to response of ≤5 minutes after NNS administration. Heroin was the substance reportedly involved in a majority (95.4%; 165/173) of these cases; fentanyl was reported to be involved in 5.2% (9/173) of the cases. Many reversals (97.6%; 248/254) involved administration of ≤2 units of NNS. Three deaths were reported (NNS was reported to have been administered too late for two cases [the individuals were deceased prior to NNS administration]; details were not provided for the third case). The most commonly reported observed events were "withdrawal" (14.3%; 28/196); "nausea", "vomiting", or "gagging/retching" (10.2%; 20/196); and "irritability" or "anger" (8.7%; 17/196). CONCLUSION: This survey of data provided by first-responder and community-based organizations indicated that NNS was successful at reversing the effects of opioid overdose in most reported cases.
OBJECTIVE:Naloxone hydrochloride, an opioid antagonist, has been approved as a concentrated 4 mg dose intranasal formulation for the emergency treatment of known or suspected opioid overdose. This new formulation is easier to use and contains a higher dose of naloxone compared with earlier, unapproved kits. A survey of first responders and community-based organizations was conducted to understand initial real-world experiences with this new formulation for opioid overdose reversal. METHODS: In August 2016, 152 US organizations known to have received units of the approved 4 mg dose/unit naloxone nasal spray (Narcan®1 nasal spray 4 mg; NNS) were surveyed regarding experiences using this formulation and availability of recorded data on these cases. Descriptive statistics were calculated based on the number of responses received for each item. RESULTS: Eight first-responder or community-based organizations provided case report data on 261 attempted overdose reversals using NNS, with survival reported for 245 cases. Successful overdose reversals were reported in 98.8% (242/245) of cases; most cases (73.5%; 125/170) reported a time to response of ≤5 minutes after NNS administration. Heroin was the substance reportedly involved in a majority (95.4%; 165/173) of these cases; fentanyl was reported to be involved in 5.2% (9/173) of the cases. Many reversals (97.6%; 248/254) involved administration of ≤2 units of NNS. Three deaths were reported (NNS was reported to have been administered too late for two cases [the individuals were deceased prior to NNS administration]; details were not provided for the third case). The most commonly reported observed events were "withdrawal" (14.3%; 28/196); "nausea", "vomiting", or "gagging/retching" (10.2%; 20/196); and "irritability" or "anger" (8.7%; 17/196). CONCLUSION: This survey of data provided by first-responder and community-based organizations indicated that NNS was successful at reversing the effects of opioid overdose in most reported cases.
Authors: Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France Journal: J Pharmacol Exp Ther Date: 2018-11-21 Impact factor: 4.030
Authors: Stephen Parkin; Joanne Neale; Caral Brown; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer Journal: Int J Drug Policy Date: 2020-04-15
Authors: Jarkko Johansson; Jussi Hirvonen; Zsófia Lovró; Laura Ekblad; Valtteri Kaasinen; Olli Rajasilta; Semi Helin; Jouni Tuisku; Saija Sirén; Mirka Pennanen; Arvind Agrawal; Roger Crystal; Petri J Vainio; Hannu Alho; Mika Scheinin Journal: Neuropsychopharmacology Date: 2019-03-13 Impact factor: 7.853
Authors: Stephen Parkin; Joanne Neale; Caral Brown; Jermaine D Jones; Laura Brandt; Felipe Castillo; Aimee N C Campbell; John Strang; Sandra D Comer Journal: Int J Drug Policy Date: 2020-10-20
Authors: Katie Kanter; Ryan Gallagher; Feyisope Eweje; Alexander Lee; David Gordon; Stephen Landy; Julia Gasior; Haideliza Soto-Calderon; Peter F Cronholm; Ben Cocchiaro; James Weimer; Alexis Roth; Stephen Lankenau; Jacob Brenner Journal: Harm Reduct J Date: 2021-07-23